These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 17640448

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 4. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 5. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K, Davies M.
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Diabetic patient experiences in a Medicaid managed care system.
    Womeodu RJ, Graney MJ, Gibson DV, Bailey JE.
    Tenn Med; 2003 Oct; 96(10):465-9. PubMed ID: 14574722
    [Abstract] [Full Text] [Related]

  • 8. Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?
    Shrank WH, Joseph GJ, Choudhry NK, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL.
    Am J Manag Care; 2006 Sep; 12(9):545-51. PubMed ID: 16961443
    [Abstract] [Full Text] [Related]

  • 9. Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus.
    Peyrot M, Rubin RR.
    Curr Med Res Opin; 2008 Aug; 24(8):2413-22. PubMed ID: 18627641
    [Abstract] [Full Text] [Related]

  • 10. Self-reported use of natural health products: a cross-sectional telephone survey in older Ontarians.
    Levine MA, Xu S, Gaebel K, Brazier N, Bédard M, Brazil K, Lohfeld L, MacLeod SM.
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):383-92. PubMed ID: 20129259
    [Abstract] [Full Text] [Related]

  • 11. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F, Rønn B, Zdravkovic M, Pieber TR.
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [Abstract] [Full Text] [Related]

  • 12. Identifying factors that affect patients' willingness to pay for inhaled insulin.
    Pinto SL, Holiday-Goodman M, Black CD, Lesch D.
    Res Social Adm Pharm; 2009 Sep; 5(3):253-61. PubMed ID: 19733826
    [Abstract] [Full Text] [Related]

  • 13. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 14. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans.
    Rossetti P, Porcellati F, Ricci NB, Candeloro P, Cioli P, Bolli GB, Fanelli CG.
    Diabetes; 2008 Mar; 57(3):746-56. PubMed ID: 18083783
    [Abstract] [Full Text] [Related]

  • 15. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A.
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [Abstract] [Full Text] [Related]

  • 16. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
    Yenigun M, Honka M.
    Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.